Accessibility Menu

Whitehawk Therapeutics

(NASDAQ) WHWK

Current Price$4.37
Market Cap$235.03M
Since IPO (2021)-83%
5 Year-84%
1 Year+124%
1 Month-3%

Whitehawk Therapeutics Financials at a Glance

Market Cap

$235.03M

Revenue (TTM)

$0.00

Net Income (TTM)

-$115.81M

EPS (TTM)

-$1.67

P/E Ratio

-2.61

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$4.37

Volume

376,298.876

Open

$4.34

Previous Close

$4.37

Daily Range

$4.14 - $4.42

52-Week Range

$1.57 - $5.50

Estimated Earnings Date

Aug 6, 2026

WHWK News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Whitehawk Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

23

CEO

David Lennon, PhD

Website

www.whitehawktx.com

Headquarters

Pacific Palisades, CA 90272, US

WHWK Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-79.63%

Return on Capital

-83.93%

Return on Assets

-91.02%

Earnings Yield

-38.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$235.03M

Shares Outstanding

53.78M

Volume

376.30K

Avg. Volume

326.74K

Financials (TTM)

Gross Profit

-$5.00K

Operating Income

-$122.70M

EBITDA

-$115.78M

Operating Cash Flow

-$97.43M

Capital Expenditure

-$552.00K

Free Cash Flow

-$97.99M

Cash & ST Invst.

$123.04M

Total Debt

$0.00

Whitehawk Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$235.03M

N/A

Market Cap/Employee

$5.88M

N/A

Employees

40

N/A

Net Income

-$22.19M

-130.4%

EBITDA

-$22.19M

-130.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$123.04M

-46.7%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-91.02%

N/A

Return on Invested Capital

-1.06%

N/A

Free Cash Flow

-$17.23M

-13.1%

Operating Cash Flow

-$17.23M

-14.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZNTLZentalis Pharmaceuticals, Inc.
$3.97+7.74%
MGNXMacroGenics, Inc.
$4.77+1.60%
OVIDOvid Therapeutics Inc.
$2.50+7.76%
ONCYOncolytics Biotech Inc.
$0.92-2.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WENWendy's
$7.86+0.26%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.36+0.03%
IBITiShares Bitcoin Trust
$33.80-0.04%
PLSMPulsenmore
$6.95+1.04%

Questions About WHWK

What is the current price of Whitehawk Therapeutics?

Whitehawk Therapeutics is trading at $4.37 per share.

What is the 52-week range for Whitehawk Therapeutics?

Over the past 52 weeks, Whitehawk Therapeutics has traded between $1.57 and $5.50.

How much debt does Whitehawk Therapeutics have?

As of the most recent reporting period, Whitehawk Therapeutics reported total debt of $0.00.

How much cash does Whitehawk Therapeutics have on hand?

Whitehawk Therapeutics reported $34.79M in cash and cash equivalents in its most recent financial results.

What is Whitehawk Therapeutics’s dividend yield?

Whitehawk Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services